scispace - formally typeset
N

Nagio Takigawa

Researcher at Kawasaki Medical School

Publications -  341
Citations -  11310

Nagio Takigawa is an academic researcher from Kawasaki Medical School. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 42, co-authored 331 publications receiving 10316 citations. Previous affiliations of Nagio Takigawa include Okayama University & Hiroshima University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells

Kazuhiko Shien, +15 more
- 15 May 2013 - 
TL;DR: The manner of EGFR-TKI exposure influences the mechanism of acquired resistance and the appearance of stem cell-like property with EGFR -TKI treatment, which is indicated to be a critical problem in the treatment of lung cancer.
Journal ArticleDOI

Phase III Trial Comparing Docetaxel and Cisplatin Combination Chemotherapy With Mitomycin, Vindesine, and Cisplatin Combination Chemotherapy With Concurrent Thoracic Radiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: OLCSG 0007

Yoshihiko Segawa, +19 more
- 10 Jul 2010 - 
TL;DR: DP chemotherapy combined with concurrent TRT is an alternative to MVP chemotherapy for patients with LA-NSCLC and shows a trend toward improved response rate, 2-year survival rate, median progression-free time, and median survival.
Journal ArticleDOI

Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non-Small Cell Lung Cancer Cell Line

Atsuko Ogino, +11 more
- 15 Aug 2007 - 
TL;DR: Interestingly, transfection of the EGFR carrying only a 15-bp deletion reversed the resistance to gefitinib in RPC-9 cells, suggesting that the balance of expression levels between gefithinib-sensitive or gef itin ib-resistant EGFR may govern the response to gEFit inib in lung cancer.
Journal ArticleDOI

The Role of STAT3 in Non-Small Cell Lung Cancer

Daijiro Harada, +2 more
- 26 Mar 2014 - 
TL;DR: The role of STAT3 and the mechanisms of treatment resistance in malignant diseases, especially NSCLC are reviewed, as STAT3 is a critical mediator of the oncogenic effects of EGFR mutations.